Delivery Order SPE2DB20D3101-SPE2DB25FRSH0
- Not listed
- The Defense Logistics Agency awarded a $1,653.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-count units). The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 5, 2025, and will be performed at the awardee's Conshohocken, Pennsylvania location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,266.71 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray. This contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 18, 2025. The product will be delivered to a location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,470.53 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on July 24, 2025, with a ceiling value of $1,583.26 and an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger indefinite delivery vehicle with DLA. This delivery order falls...
- The Defense Logistics Agency awarded a $3,712.29 firm fixed price delivery order to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-pack units) with an ultimate completion date of August 1, 2025. This non-set-aside contract was awarded competitively and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,301.63 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray (2-pack units) on July 23, 2025, with completion required by July 24, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $1,673.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on July 25, 2025, with completion targeted for July 28, 2025. This non-set-aside award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,620.80 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray (2-count units). This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child action under a larger contract vehicle, this delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $7,839.08 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2 units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract is non-set-aside and was competitively awarded. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a typical...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-count units) with a ceiling value of $5,716.32. This firm fixed-price delivery order is set to be completed by August 12, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This award represents a competitive procurement with no set-aside designation, reflecting the contractor's...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRSH0Delivery Order
The Defense Logistics Agency awarded a $11,472.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-count units). This is a non-set-aside contract with an ultimate completion date of August 12, 2025, and represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order supports the Defense Logistics Agency's pharmaceutical supply mission to the military health system and related federal healthcare customers. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a comprehensive portfolio of federal medical contracts and serves as a critical vendor for military and veteran healthcare procurement. The award of naloxone nasal spray reflects the agency's continued focus on ensuring availability of emergency medical supplies, including opioid overdose reversal medications, across the defense healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.5k | 8/11/25 |